Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA and State College, PA: December 3, 2009 - Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics’ NextGENe® Software for next-generation sequencing projects performed at Ambry Genetics.
Anja Kammesheidt PhD, Ambry’s CSO said, "Our team at Ambry has been providing genomics solutions on Illumina’s® Genome Analyzer platform for 2 years now. In light of diversifying applications, increasing project sizes, and new genomes to be explored, having a proven and innovative partner for bioinformatics is key. While some of our clients are interested in performing their own analyses, others are asking for extended support. We have been impressed with SoftGenetics’ Software tools, as well as their approach to take care of the clients’ needs which is very much in line with Ambry’s philosophy. We are looking forward to working together to provide tailored services to our clients."
Jonathan Liu PhD, SoftGenetics VP Research & Development echoed Dr. Kammesheidt’s thoughts and added that "the SoftGenetics/Ambry partnership provides a new strategic alliance that will not only provide a single streamlined source for next-generation sequencing researchers but will also provide SoftGenetics with a deepened vision of future researcher requirements, allowing NextGENe to remain at the forefront of next-generation sequencing software." "This highly unique alliance", continued John Fosnacht, SoftGenetics VP Sales & Marketing, "provides researchers wishing to utilize the power of next-generation sequencing a distinctive value proposition by combining the technical quality of Ambry Genetics sequencing with the unique analysis capabilities of NextGENe® without the heavy investment typically required in next-generation sequencing instrumentation and bioinformatics. We all believe this is a true win-win situation for everyone."
"Next-generation sequencing services are more valuable to any scientific researcher if you can offer a full menu for bioinformatics support" said Ardy Arianpour, Director of Business Development, Genomic Services at Ambry Genetics. "Ambry Genetics has now become the genomics community’s one-stop service shop for next-generation sequencing services. We can handle large projects and we can offer the most robust data analysis through the exclusive alliance with SoftGenetics. "
Ambry Genetics has been providing next generation sequencing services to pharmaceutical, biotech and academic clients for a wide range of applications including targeted resequencing through custom or exome sequence capture, transcriptome, ChIP and de novo sequencing. Ambry Genetics is focused on delivering the highest quality results with the most sensible workflows while maintaining cost effective contracts for the genomics community.
SoftGenetics, LLC, located in State College Pennsylvania specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy-to use Windows® user interface. Its NextGENe® software provides biologists with an easy-to-use software analysis tool which improves Next Generation Sequencing accuracy in a complete, freestanding Windows® based program. NextGENe® virtually eliminates bioinformatics requirements, utilizes low cost hardware, and is compatible with all major NGS systems. To learn more, or to request a 30-day trial of the software, please visit: SoftGenetics at www.softgenetics.com.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com